bioRxiv Science⌕ Search

Biology subjects

Jocoy, E. L.

Publications and source records attributed to Jocoy, E. L..

2 recordsLinked to original sources

ACDA: Implementation of an Augmented Drug Synergy Prediction Algorithm

MotivationDrug synergy prediction is a complex problem typically approached with machine learning techniques using molecular data, pharmacological data, and knowledge of biological-interaction networks. The recently published Cancer Drug Atlas (CDA) uses a logistic regression model to predict a binary synergy outcome in cell-line models by utilizing drug target information, knowledge of genes mutated in each model, and the models monotherapy drug sensitivity. However, we observed low performance, 0.33, of the CDA measured by Pearson correlation of predicted versus measured sensitivity when we evaluated datasets from six studies that were not considered during the development of the CDA. Here we describe improvements to the CDA algorithm, the Augmented CDA, that improved performance by 71% and robustness to dataset variations in drug response values. ResultsWe augmented the drug-synergy prediction-modeling approach CDA described in Narayan et al. by applying a random forest regression and optimization via cross-validation hyper-parameter tuning. We benchmarked the performance of our Augmented CDA (ACDA) compared to the original CDA algorithm using datasets from DrugComb, an open-access drug-combination screening data resource. The ACDAs performance is 71% higher than that of the CDA when trained and validated on the same dataset spanning ten tissues. The ACDA performs marginally better (6% increase) than the CDA when trained on one dataset and validated on another dataset in 22 cases that cover seven tissues. We also compared the performance of ACDA to one of the winners of the DREAM Drug Combination Prediction Challenge (Mikhail Zaslavskiys algorithm which we denoted as EN). The performance of EN was smaller than that of the ACDA in 15 out of 19 cases. In addition to data from cell lines, we also trained the ACDA algorithm on Novartis Institutes for BioMedical Research PDX encyclopedia (NIBR PDXE) data and generated sensitivity predictions for the cases where drug-combination tumor-volume measurements were unavailable. Finally, we developed an approach to visualize synergy-prediction data using dendrograms and heatmaps instead of the Voronoi diagrams used in the CDA. The latter has a complex algorithmic realization and no publicly available implementation, whereas the ACDA visualization approach is more transparent and has open access. We implemented and wrapped the ACDA algorithm in an easy-to-use python package available from PyPI. AvailabilityThe source code is available at https://github.com/TheJacksonLaboratory/drug-synergy, and the software package can be installed directly from PyPI using pip. ContactAnuj.Srivastava@jax.org, Carol.Bult@jax.org

bioinformatics↗

A Genomically and Clinically Annotated Patient Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer

Patient-derived xenograft models (PDXs) are an effective preclinical in vivo platform for testing the efficacy of novel drug and drug combinations for cancer therapeutics. Here we describe a repository of 79 genomically and clinically annotated lung cancer PDXs available from The Jackson Laboratory that have been extensively characterized for histopathological features, mutational profiles, gene expression, and copy number aberrations. Most of the PDXs are models of non-small cell lung cancer (NSCLC), including 37 lung adenocarcinoma (LUAD) and 33 lung squamous cell carcinoma (LUSC) models. Other lung cancer models in the repository include four small cell carcinomas, two large cell neuroendocrine carcinomas, two adenosquamous carcinomas, and one pleomorphic carcinoma. Models with both de novo and acquired resistance to targeted therapies with tyrosine kinase inhibitors are available in the collection. The genomic profiles of the LUAD and LUSC PDX models are consistent with those observed in patient tumors of the same tumor type from The Cancer Genome Atlas (TCGA) and to previously characterized gene expression-based molecular subtypes. Clinically relevant mutations identified in the original patient tumors were confirmed in engrafted tumors. Treatment studies performed for a subset of the models recapitulated the responses expected based on the observed genomic profiles. SignificanceThe collection of lung cancer Patient Derived Xenograft (PDX) models maintained at The Jackson Laboratory retain both the histologic features and treatment-relevant genomic alterations observed in the originating patient tumors and show expected responses to treatment with standard-of-care agents. The models serve as a valuable preclinical platform for translational cancer research. Information and data for the models are freely available from the Mouse Models of Human Cancer database (MMHCdb, http://tumor.informatics.jax.org/mtbwi/pdxSearch.do).

cancer biology↗